FDA Fast Track Designation is Intended to Expedite the Development and Review of New Drugs to Treat Serious Medical Conditions that Fill Unmet Medical Need --
-- Phase 3 ARTEST Registration Study of Enobosarm in Patients with AR+ ER+ HER2- Metastatic Breast Cancer Who Have Shown Previous Disease Progression on a Nonsteroidal AI, Fulvestrant, and a CDK 4/6 Inhibitor is Currently Enrolling --
https://finance.yahoo.com/news/veru-announces-fda-grant-fast-133000315.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.